Pinnacle Wealth Planning Services’s Acadia Pharmaceuticals ACAD Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$266K	Sell	10,503 -96	-0.9%	-$2.11K	0.03%	420
2026 Q1	$236K	Sell	10,599 -594	-5%	-$14.2K	0.02%	421
2025 Q4	$299K	Sell	11,193 -282	-2%	-$6.74K	0.03%	327
2025 Q3	$245K	Buy	11,475 +1	+0%	+$24	0.03%	386
2025 Q2	$247K	Buy	+11,474	New	+$213K	0.03%	353
2021 Q1	–	Sell	-3,639	Closed	-$195K	–	354
2020 Q4	$195K	Buy	+3,639	New	+$181K	0.05%	287

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Pinnacle Wealth Planning Services's ACAD Position: Q2 2026 in Review

Pinnacle Wealth Planning Services reduced its Acadia Pharmaceuticals (ACAD) stake by 0.91% in Q2 2026, selling an estimated $2.11K and leaving 10,503 shares worth $266K. The position accounts for 0.03% of the portfolio, ranked #420.

Pinnacle Wealth Planning Services first reported a position in ACAD in Q4 2020 and has held it in 6 quarters since. The position peaked at $299K in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Pinnacle Wealth Planning Services held 10,503 shares of Acadia Pharmaceuticals worth $266K as of Q2 2026.
Pinnacle Wealth Planning Services sold 96 Acadia Pharmaceuticals shares in Q2 2026, an estimated $2.11K.
Acadia Pharmaceuticals made up 0.03% of Pinnacle Wealth Planning Services's portfolio in Q2 2026, its #420 holding.
Pinnacle Wealth Planning Services first reported a position in Acadia Pharmaceuticals in Q4 2020 and has held it in 6 quarters since.
Pinnacle Wealth Planning Services's Acadia Pharmaceuticals position peaked at $299K in Q4 2025.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q2 2026, filed 7 Aug 2026.